Qualitative case study examines ibogaine's effects on opioid detoxification and user motivations, suggesting implications for treatment practices.
Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was used to examine the experiences and motivations of 10 opioid-dependent individuals who used ibogaine for opioid detoxification. Participants were recruited through ibogaine networks, OST services, and snowball sampling. Semi-structured interviews were conducted and analyzed using an inductive thematic analysis approach, informed by an interpretive, experiential framework. Analysis focused on how participants understood their motivations, treatment processes, safety practices, and post-treatment outcomes. Seven themes were identified: "Desperation to be opioid free," "motivations for using ibogaine," "safety conscious and support seeking," "improving ibogaine practices," "effects of treatment on depression and anxiety," "effects of treatment on dependence," and "the spiritual effect." Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases. Preparation, medical screening, and post-treatment psychosocial support were critical to positive outcomes. This study adds to the literature by documenting experiences of ibogaine use, with implications for clinical practice, policy, and future research.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: